Investigación

Leucemia y hemopatías pediátricas

Buscador de publicaciones

Publicaciones

  • Vives-Corrons JL, Krishnevskaya E, Hernández-Rodriguez I, Payán-Pernia S, Sevilla ÁFR and Badell-Serra I.

    Red cell ektacytometry in two patients with chronic hemolytic anemia and three new alpha-spectrin variants

    ANNALS OF HEMATOLOGY . 101(3): 549-555. Nº de citas: 1

    [doi:10.1007/s00277-021-04723-5]

  • Marina Caballero Bellón, Faura A, Margarit A, Bobillo-Perez S, Català-Temprano A, Alonso-Saladrigues A, Conde N, Balaguer-Gargallo M, Rives-Solà S and Jordán-García I.

    Outcomes for paediatric acute leukaemia patients admitted to the paediatric intensive care unit

    EUROPEAN JOURNAL OF PEDIATRICS . 181(3): 1037-1045. Nº de citas: 6

    [doi:10.1007/s00431-021-04292-9]

  • Buechner J, Caruana I, Künkele A, Rives-Solà S, Vettenranta K, Bader P, Peters C, Baruchel A and Calkoen FG.

    Chimeric Antigen Receptor T-Cell Therapy in Paediatric B-Cell Precursor Acute Lymphoblastic Leukaemia: Curative Treatment Option or Bridge to Transplant?

    Frontiers in pediatrics . 9: 784024-784024. Nº de citas: 15

    [doi:10.3389/fped.2021.784024]

  • Pulsipher MA, Han X, Maude SL, Laetsch TW, Qayed M, Rives-Solà S, Boyer MW, Hiramatsu H, Yanik GA, Driscoll T, Myers GD, Bader P, Baruchel A, Buechner J, Stefanski HE, Kalfoglou C, Nguyen K, Waldron ER, Thudium Mueller K, Maier HJ, Kari G and Grupp SA.

    Next-Generation Sequencing of Minimal Residual Disease for Predicting Relapse after Tisagenlecleucel in Children and Young Adults with Acute Lymphoblastic Leukemia

    blood cancer discovery . 3(1): 66-81. Nº de citas: 86

    [doi:10.1158/2643-3230.BCD-21-0095]

  • Antic Ž, Yu J, Bornhauser BC, Lelieveld SH, van der Ham CG, van Reijmersdal SV, Morgado L, Elitzur S, Bourquin JP, Cazzaniga G, Eckert C, Camós-Guijosa M, Sutton R, Cavé H, Moorman AV, Sonneveld E, Geurts van Kessel A, van Leeuwen FN, Hoogerbrugge PM, Waanders E and Kuiper RP.

    Clonal dynamics in pediatric B-cell precursor acute lymphoblastic leukemia with very early relapse.

    PEDIATRIC BLOOD & CANCER . 69(1): . Nº de citas: 9

    [doi:10.1002/pbc.29361]

  • Maurer-Granofszky M, Schumich A, Buldini B, Gaipa G, Kappelmayer J, Mejstrikova E, Karawajew L, Rossi J, Suzan AÇ, Agriello E, Anastasiou-Grenzelia T, Barcala V, Barna G, Batinic D, Bourquin JP, Brüggemann M, Bukowska-Strakova K, Burnusuzov H, Carelli D, Deniz G, Dubravcic K, Feuerstein T, Gaillard MI, Galeano A, Giordano H, Gonzalez A, Groeneveld-Krentz S, Hevessy Z, Hrusak O, Iarossi MB, Jáksó P, Kloboves Prevodnik V, Kohlscheen S, Kreminska E, Maglia O, Malusardi C, Marinov N, Martin BM, Möller C, Nikulshin S, Palazzi J, Paterakis G, Popov A, Ratei R, Rodríguez C, Sajaroff EO, Sala S, Samardzija G, Sartor M, Scarparo P, Sedek L, Slavkovic B, Solari L, Svec P, Szczepanski T, Taparkou A, Torrebadell-Burriel M, Tzanoudaki M, Varotto E, Vernitsky H, Attarbaschi A, Schrappe M, Conter V, Biondi A, Felice M, Campbell M, Kiss C, Basso G, Dworzak MN and On Behalf Of I-Bfm-Flow-Network.

    An Extensive Quality Control and Quality Assurance (QC/QA) Program Significantly Improves Inter-Laboratory Concordance Rates of Flow-Cytometric Minimal Residual Disease Assessment in Acute Lymphoblastic Leukemia: An I-BFM-FLOW-Network Report

    Cancers . 13(23): 6148. Nº de citas: 21

    [doi:10.3390/cancers13236148]

  • Ortiz-Maldonado V, Rives-Solà S, Español-Rego M, Alonso-Saladrigues A, Montoro M, Magnano L, Giné E, Pascal M, Díaz-Beyá M, Castella M, Català-Temprano A, Faura A, Rodríguez-Lobato LG, Oliver-Caldes A, Martínez-Roca A, Rovira M, González-Navarro EA, Ortega JR, Cid J, Lozano M, Garcia-Rey E, Fernández S, Castro P, Jordán-García I, Villamor N, Aymerich M, Torrebadell-Burriel M, Deyà-Martinez A, Fernández de Larrea C, Benitez-Ribas D, Trias E, Varea S, Calvo G, Esteve J, Urbano-Ispizua A, Juan-Otero M and Delgado J.

    Factors associated with the clinical outcome of patients with relapsed/refractory CD19 + acute lymphoblastic leukemia treated with ARI-0001 CART19-cell therapy

    Journal for ImmunoTherapy of Cancer . 9(12): 3644. Nº de citas: 15

    [doi:10.1136/jitc-2021-003644]

  • Mesegue-Meda M, Alonso-Saladrigues A, Pérez-Jaume S, Comes-Escoda A, Dapena JL, Faura A, Conde N, Català-Temprano A, Ruiz-Llobet A, Zapico-Muñiz E, Camós-Guijosa M and Rives-Solà S.

    Lower incidence of clinical allergy with PEG-asparaginase upfront versus the sequential use of native E. coli asparaginase followed by PEG-ASP in pediatric patients with acute lymphoblastic leukemia

    HEMATOLOGICAL ONCOLOGY . 39(5): 687-696. Nº de citas: 7

    [doi:10.1002/hon.2914]

  • Rubio-San-Simón A, Hladun Alvaro R, Juan Ribelles A, Castañeda-Heredia A, Guerra-García P, Verdú-Amorós J, Andrés M, Cañete A, Rives-Solà S, Pérez-Martínez A, Mora J, Patiño-García A, Lassaleta A, Llort A, Ramírez M, Mata C, Gallego S, Martín-Broto J, Cruz-Martínez O, Morales-La Madrid A, Solano P, Martínez Romera I, Fernández-Teijeiro A, Bautista F and Moreno L.

    The paediatric cancer clinical research landscape in Spain: a 13-year multicentre experience of the new agents group of the Spanish Society of Paediatric Haematology and Oncology (SEHOP)

    CLINICAL & TRANSLATIONAL ONCOLOGY . 23(12): 2489-2496. Nº de citas: 4

    [doi:10.1007/s12094-021-02649-y]

  • Payán-Pernía S, Ruiz-Llobet A, Remacha Sevilla ÁF, Egido J, Ballarín Castán JA and Moreno JA.

    Sickle cell nephropathy. Clinical manifestations and new mechanisms involved in kidney injury.

    nefrologia . 41(4): 373-382.

    [doi:10.1016/j.nefroe.2021.10.001]